We use cookies to see how investors use El Fondo and make its tools, data and markets better for you. You can accept or reject; essential cookies always stay on. Privacy Policy
Trades about 136% below its sector, cheaper than its peers on earnings.
BINEX Co., Ltd. operates as a pharmaceutical enterprise based in South Korea. The company provides an extensive array of medicinal products, encompassing bisroot items, gastrointestinal treatments (including antispasmodics and antiulcerants), NSAIDs, cardiovascular and urology medications, hepatic protective agents, topical ointments and creams, ophthalmic solutions, CNS agents, digestive aids, remedies for constipation and circulation, antibiotics and antifungals, cough and cold preparations, vitamins and nutritional supplements, antihistamines, antivertigo agents, and over-the-counter (OTC) drugs. Additionally, BINEX Co., Ltd. maintains a co-development alliance with Genexine, Inc. focused on the creation of a COVID-19 vaccine. Founded in 1957, its headquarters are situated in Incheon, South Korea.
Loading the full price history…
Run your own numbersPast performance is not a forecast.
Save 053030.KQ and get told when something moves.
Get updates
A clear, direct weekly summary.
Learn the fundamentals behind this asset.
A stock is a fraction of ownership in a real company. Buy one share and you own a piece (usually a tiny piece) of every desk, factory, contract and brand the company runs. The price moves because the market keeps revising what that whole pie is worth.
The price-to-earnings ratio is how much investors are paying for one dollar of a company's profit. A multiple, never an absolute. Always compared to something: a sector, a region, the company's own past.
Dividend yield is the annual income a stock or ETF pays out, expressed as a percentage of what you paid for it. It is the visible part of total return: the cash that lands in your account every quarter, and the lever most retail investors actually feel.
Market cap is shares times price. A simple formula that produces wildly unequal numbers: a single US tech name can be worth more than every company on a LATAM exchange combined.
